Roivant 10-Q: $4.2B Cash, $191.6M Quarterly Loss, New Immunovant Derivative Suit
ROIV has more than doubled off its 52-week low of $19.79.
Summary
Roivant's Q2 10-Q shows $4.21 billion in cash and securities and a $191.6 million quarterly loss, with a new Immunovant derivative lawsuit and a CEO share-donation agreement disclosed alongside the already-reported LISRAYA launch numbers.
Key Events · Earnings and Guidance · ROIV
-
Q2 Loss Widens on Genevant Distribution
Net loss attributable to Roivant was $191.6 million versus $113.5 million a year earlier; the Genevant dividend-equivalent distribution added $95.9 million, or $0.13 per share, to the loss.
-
Cash Position $4.21 Billion
Cash, cash equivalents and marketable securities totaled $4.21 billion at September 30, 2026, down from $4.29 billion at March 31, 2026; management says this funds operations into profitability.
-
New Immunovant Derivative Lawsuit
Filed in Delaware Chancery in September 2026, the suit names Roivant as Immunovant's controlling stockholder over the January 2025 private placement; damages are unspecified and the company says the claims are without merit.
-
Buybacks and ATM Capacity Unchanged
Roivant repurchased 9,359,498 shares for $281.2 million in the six months, leaving $609.3 million on the authorization; the $400.0 million ATM facility remains fully undrawn.
Analysis · ROIV · Life Sciences
The headline numbers are already out — LISRAYA's $31.0 million in first-five-week sales and the IMVT-1402 rheumatoid arthritis win — but the 10-Q carries the balance sheet behind them: $4.21 billion of cash and securities, which management says funds operations into profitability. The loss attributable to Roivant widened to $191.6 million from $113.5 million, inflated not by operations but by a $95.9 million dividend-equivalent distribution to Genevant equity awards tied to the Moderna settlement. Two governance items are new here. First, a Delaware derivative suit names Roivant as Immunovant's controlling stockholder over the January 2025 private placement. Second, a CEO letter agreement lets Matthew Gline donate PSU shares to a donor-advised fund while shifting a two-year lockup onto 109% as many option shares. Neither is quantified, but the derivative suit is an unquantified overhang on a 55%-owned subsidiary.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ROIV was trading at $41.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.1B. The 52-week trading range was $19.79 to $42.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.